Xeljanz? So now pharma execs are just naming drugs after whatever's in the Scrabble rack in front of them?
— Charles Brower (@Carbrovian) October 14, 2013
The generic name — tofacitinib — is not exactly euphonious either. But Xeljanz? Huh? Nancy Friedman? Anyone?
Oh, and Pfizer thinks highly of this stuff: it’s two grand a month. Wholesale. No credit for knowing that the pill was originally developed by a guy from the National Institutes of Health.